GLASSIA
STN: 125325
Proper Name: Alpha-1-Proteinase Inhibitor (Human)
Tradename: GLASSIA
Manufacturer: Takeda Pharmaceuticals U.S.A., Inc
Indication:
- Alpha-1 Proteinase Inhibitor (human), Kamada-API, indicated for chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha1-proteinase inhibitor (Alpha1-PI), also known as alpha1- antitrypsin deficiency
Product Information
Supporting Documents
- September 27, 2022 Approval Letter - GLASSIA
- Supporting Documents older than three years - GLASSIA
- Approval History, Letters, Reviews, and Related Documents - GLASSIA
Related Information
- FDA Online Label Repository
Search this database for drug labeling and other information. The content has not been altered or verified by the FDA and may not be the labeling on currently distributed products or identical to the labeling that is approved.